Menu Search
Equities

Everest Medicines Ltd

1952:HKG

Everest Medicines Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)34.65
  • Today's Change-1.60 / -4.41%
  • Shares traded2.81m
  • 1 Year change+31.75%
  • Beta2.6594
Data delayed at least 15 minutes, as of Nov 13 2024 05:17 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Cash flow in CNYView more

In 2023, Everest Medicines Ltd increased its cash reserves by 6.58%, or 32.28m. Cash Flow from Investing totalled 752.50m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 769.19m for operations while cash generated from financing totalled 10.10m.
Cash flow per share-3.20
Price/Cash flow per share--
Book value per share14.89
Tangible book value per share7.50
More ▼

Balance sheet in CNYView more

Everest Medicines Ltd has a Debt to Total Capital ratio of 11.19%, a higher figure than the previous year's 5.61%.
Current ratio4.68
Quick ratio4.62
Total debt/total equity0.1261
Total debt/total capital0.1119
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.